OpenLB
Open Library of Bioscience
Advanced Search
Scientific reports
05 25, 2016;6 26511.

Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine.

Harald Nothaft, Brandi Davis, Yee Ying Lock, Maria Elisa Perez-Munoz, Evgeny Vinogradov, Jens Walter, Colin Coros, Christine M Szymanski
Author Information
  1. Harald Nothaft: Department of Biological Sciences, University of Alberta, Edmonton, Canada.
  2. Brandi Davis: Delta Genomics, Edmonton, Canada.
  3. Yee Ying Lock: Delta Genomics, Edmonton, Canada.
  4. Maria Elisa Perez-Munoz: Department of Agricultural, Food &Nutritional Science, University of Alberta, Edmonton, Canada.
  5. Evgeny Vinogradov: Human Health Therapeutics, National Research Council, Ottawa, Canada.
  6. Jens Walter: Department of Biological Sciences, University of Alberta, Edmonton, Canada.
  7. Colin Coros: Delta Genomics, Edmonton, Canada.
  8. Christine M Szymanski: Department of Biological Sciences, University of Alberta, Edmonton, Canada.
PMID: 27221144 DOI: 10.1038/srep26511

Abstract

Campylobacter jejuni is a predominant cause of human gastroenteritis worldwide. Source-attribution studies indicate that chickens are the main reservoir for infection, thus elimination of C. jejuni from poultry would significantly reduce the burden of human disease. We constructed glycoconjugate vaccines combining the conserved C. jejuni N-glycan with a protein carrier, GlycoTag, or fused to the Escherichia coli lipopolysaccharide-core. Vaccination of chickens with the protein-based or E. coli-displayed glycoconjugate showed up to 10-log reduction in C. jejuni colonization and induced N-glycan-specific IgY responses. Moreover, the live E. coli vaccine was cleared prior to C. jejuni challenge and no selection for resistant campylobacter variants was observed. Analyses of the chicken gut communities revealed that the live vaccine did not alter the composition or complexity of the microbiome, thus representing an effective and low-cost strategy to reduce C. jejuni in chickens and its subsequent entry into the food chain.

References

  1. Infect Immun. 2009 Dec;77(12):5437-48 [PMID: 19737895]
  2. Poult Sci. 2014 Nov;93(11):2779-87 [PMID: 25214556]
  3. J Nanobiotechnology. 2012 Mar 21;10:12 [PMID: 22436172]
  4. Infect Immun. 1982 Dec;38(3):898-906 [PMID: 7152677]
  5. Infect Immun. 2000 Oct;68(10):5679-89 [PMID: 10992471]
  6. Risk Anal. 2006 Dec;26(6):1613-21 [PMID: 17184401]
  7. Antimicrob Agents Chemother. 2002 Jul;46(7):2124-31 [PMID: 12069964]
  8. Anal Chem. 2008 Jul 15;80(14):5468-75 [PMID: 18547063]
  9. J Microbiol Biotechnol. 2014 Feb 28;24(2):217-24 [PMID: 24225374]
  10. Anal Biochem. 2005 Apr 1;339(1):69-72 [PMID: 15766712]
  11. Infect Immun. 1991 Mar;59(3):1100-5 [PMID: 1705240]
  12. J Microbiol Biotechnol. 2014 Mar 28;24(3):363-70 [PMID: 24346471]
  13. Clin Diagn Lab Immunol. 1996 Nov;3(6):669-77 [PMID: 8914757]
  14. An Acad Bras Cienc. 2005 Jun;77(2):293-324 [PMID: 15895165]
  15. FEMS Microbiol Lett. 2007 Jul;272(2):137-43 [PMID: 17521366]
  16. EMBO J. 2006 Mar 8;25(5):967-76 [PMID: 16498400]
  17. Mol Cell Proteomics. 2011 Feb;10(2):M000031-MCP201 [PMID: 20360033]
  18. Nature. 2000 Feb 10;403(6770):665-8 [PMID: 10688204]
  19. Infect Immun. 1983 Oct;42(1):276-84 [PMID: 6618667]
  20. J Biol Chem. 2002 Nov 8;277(45):42530-9 [PMID: 12186869]
  21. Foodborne Pathog Dis. 2009 Sep;6(7):755-65 [PMID: 19425824]
  22. PLoS One. 2011;6(5):e20084 [PMID: 21625391]
  23. J Biol Chem. 2003 Sep 5;278(36):34090-101 [PMID: 12819207]
  24. Prev Vet Med. 2013 Aug 1;111(1-2):100-11 [PMID: 23706344]
  25. Vaccine. 2010 Jan 22;28(4):1094-105 [PMID: 19853682]
  26. World J Microbiol Biotechnol. 2014 Jan;30(1):281-92 [PMID: 23913025]
  27. J Infect Dis. 1997 Dec;176 Suppl 2:S122-4 [PMID: 9396694]
  28. Mol Syst Biol. 2006;2:2006.0008 [PMID: 16738554]
  29. World J Gastroenterol. 2007 Jan 28;13(4):600-6 [PMID: 17278228]
  30. Biopolymers. 2013 Oct;99(10):772-83 [PMID: 23749285]
  31. Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):15019-24 [PMID: 19706478]
  32. Mol Microbiol. 2000 Aug;37(3):501-14 [PMID: 10931344]
  33. Mol Microbiol. 1997 Mar;23(6):1089-97 [PMID: 9106201]
  34. Mol Microbiol. 2006 Sep;61(6):1646-59 [PMID: 16899076]
  35. Clin Infect Dis. 2001 Apr 15;32(8):1201-6 [PMID: 11283810]
  36. Infect Immun. 2013 May;81(5):1674-82 [PMID: 23460522]
  37. Infect Immun. 1991 Jul;59(7):2259-64 [PMID: 2050397]
  38. Vaccine. 2007 Jul 26;25(30):5548-57 [PMID: 17224215]
  39. Microbiology. 1994 Jan;140 ( Pt 1):49-57 [PMID: 7512872]
  40. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3016-21 [PMID: 15703289]
  41. Clin Vaccine Immunol. 2011 Mar;18(3):449-54 [PMID: 21177910]
  42. Nat Rev Microbiol. 2010 Nov;8(11):765-78 [PMID: 20948550]
  43. Avian Dis. 1995 Oct-Dec;39(4):812-20 [PMID: 8719215]
  44. Foodborne Pathog Dis. 2013 Jul;10(7):624-31 [PMID: 23742296]
  45. Infect Immun. 2002 Apr;70(4):2242-4 [PMID: 11895996]
  46. Infect Immun. 2009 Mar;77(3):1128-36 [PMID: 19114545]
  47. J Vaccines Vaccin. 2010 Jan 1;1(3):null [PMID: 22140651]
  48. Appl Environ Microbiol. 2015 Apr;81(7):2455-65 [PMID: 25616794]
  49. Mol Microbiol. 2005 Mar;55(6):1695-703 [PMID: 15752194]
  50. Virulence. 2010 Nov-Dec;1(6):546-50 [PMID: 21178500]
  51. J Med Entomol. 2014 May;51(3):670-7 [PMID: 24897861]
  52. Clin Vaccine Immunol. 2012 Feb;19(2):113-9 [PMID: 22155767]
  53. Science. 2002 Nov 29;298(5599):1790-3 [PMID: 12459590]
  54. Methods Mol Biol. 2010;600:227-43 [PMID: 19882132]
  55. Nat Med. 2011 Nov 20;17(12):1602-9 [PMID: 22101769]
  56. Clin Vaccine Immunol. 2012 Sep;19(9):1426-31 [PMID: 22787197]
  57. Annu Rev Genet. 2006;40:307-33 [PMID: 17094739]
  58. Glycoconj J. 2013 Jul;30(5):511-22 [PMID: 23053636]
  59. Vaccine. 2004 Mar 29;22(11-12):1379-89 [PMID: 15063560]
  60. Poult Sci. 2013 Aug;92(8):2201-11 [PMID: 23873570]
  61. J Biol Chem. 2003 Jul 4;278(27):24509-20 [PMID: 12716884]
  62. Avian Dis. 1988 Apr-Jun;32(2):330-4 [PMID: 3401176]
  63. Mol Cell Proteomics. 2012 Nov;11(11):1203-19 [PMID: 22859570]
  64. Infect Immun. 2002 Feb;70(2):787-93 [PMID: 11796612]
  65. Carbohydr Res. 2013 Jan 25;366:45-9 [PMID: 23261782]
  66. J Biol Chem. 1993 Sep 5;268(25):18717-25 [PMID: 8360165]
  67. J Biomed Biotechnol. 2010;2010:null [PMID: 20936115]
  68. J Med Entomol. 2011 Nov;48(6):1202-9 [PMID: 22238880]
  69. J Biol Chem. 2013 Mar 8;288(10):6912-20 [PMID: 23329827]
  70. Curr Opin Neurol. 2005 Oct;18(5):557-61 [PMID: 16155440]
  71. Protein Expr Purif. 2007 Feb;51(2):170-8 [PMID: 16950635]
  72. Front Cell Infect Microbiol. 2012 Feb 15;2:7 [PMID: 22919599]
  73. Vaccine. 2012 Mar 30;30(16):2683-8 [PMID: 22342500]
  74. J Biol Chem. 1998 Apr 10;273(15):8849-59 [PMID: 9535865]
  75. EMBO J. 2006 May 3;25(9):1957-66 [PMID: 16619027]
  76. Vaccine. 2005 Jul 29;23(34):4315-21 [PMID: 16005742]

MeSH Term

Animals
Bacterial Vaccines
Campylobacter Infections
Campylobacter jejuni
Chickens
Escherichia coli
Poultry Diseases

Chemicals

Bacterial Vaccines
Journal Article
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0jejuniCchickensvaccineCampylobacterhumanthusreduceglycoconjugateN-glycancoliElivechickeneffectivepredominantcausegastroenteritisworldwideSource-attributionstudiesindicatemainreservoirinfectioneliminationpoultrysignificantlyburdendiseaseconstructedvaccinescombiningconservedproteincarrierGlycoTagfusedEscherichialipopolysaccharide-coreVaccinationprotein-basedcoli-displayedshowed10-logreductioncolonizationinducedN-glycan-specificIgYresponsesMoreoverclearedpriorchallengeselectionresistantcampylobactervariantsobservedAnalysesgutcommunitiesrevealedaltercompositioncomplexitymicrobiomerepresentinglow-coststrategysubsequententryfoodchainEngineeringcreate

Similar Articles

Cited By